What is RTS,S AS01 vaccine?

What is RTS,S AS01 vaccine?

RTS,S/AS01 (RTS,S) is a vaccine that acts against Plasmodium falciparum, the deadliest malaria parasite globally and the most prevalent in Africa. * In January 2016, the vaccine was recommended by WHO for pilot introduction in selected areas of 3 African countries.

What does RTS,S stand for malaria vaccine?

RTS,S is a scientific name given to this malaria vaccine candidate and represents its composition. The ‘R’ stands for the central repeat region of Plasmodium (P.) falciparum circumsporozoite protein (CSP); the ‘T’ for the T-cell epitopes of the CSP; and the ‘S’ for hepatitis B surface antigen (HBsAg).

What is AS01 adjuvant?

The Adjuvant System AS01 is a liposome-based adjuvant which contains two immunostimulants, 3-O-desacyl-4′-monophosphoryl lipid A (MPL) and QS-21. 2. MPL is a non-toxic derivative of the lipopolysaccharide from Salmonella minnesota.

What is the RTS,S vaccine made of?

The liquid adjuvant is used to reconstitute the RTS,S lyophilized antigen such that 1 vial of each produces 2 doses of vaccine for intramuscular injection. The RTS,S component is based on a large segment of the CSP (Amino acids 207 to 395 of the CSP from NF54 strain of P. falciparum).

How does the RTS,S vaccine work?

RTS,S Development RTS,S aims to trigger the immune system to defend against the first stages when the Plasmodium falciparum malaria parasite enters the human host’s bloodstream through a mosquito bite and infects liver cells.

Which vaccine antigen is the RTS,S vaccine based on?

RTS,S was developed by GSK and the Walter Reed Army Institute of Research (WRAIR) in a collaboration that spanned more than two decades. The vaccine is based on the circumsporozoite (CS) protein of P.

What is an AS 01 position?

INVENTORY AS-01/CR-05 – Administrative Assistant and Other Clerical Positions.

What does malaria vaccine contain?

The vaccine consists of the schizont export protein (5.1) and 19 repeats of the sporozoite surface protein [NANP]. Limitations of the technology exist as it contains only 20% peptide and has low levels of immunogenicity. It also does not contain any immunodominant T-cell epitopes.

How is a recombinant vaccine made?

A recombinant vaccine is a vaccine produced through recombinant DNA technology. This involves inserting the DNA encoding an antigen (such as a bacterial surface protein) that stimulates an immune response into bacterial or mammalian cells, expressing the antigen in these cells and then purifying it from them.

Who created RTS,S vaccine?

The RTS,S vaccine was conceived of and created in the late 1980s by scientists working at SmithKline Beecham Biologicals (now GlaxoSmithKline (GSK) Vaccines) laboratories in Belgium….RTS,S.

Vaccine description
Routes of administration intramuscular injection (0.5 mL)
Legal status
Legal status In general: ℞ (Prescription only)

What is a recombinant DNA vaccine?

What is the partnership between GSK and BMGF?

GSK and BMGF will invest a combined $1.8 million in early stage research into vaccine thermostability. Most vaccines must be kept cold and transported under constant refrigeration via a so-called ‘cold chain’ which is a significant challenge in hot, remote and resource-limited regions.

How does GSK help people in the world?

GSK – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com.

What’s the name of the GSK malaria vaccine?

GSK’s malaria candidate vaccine, Mosq… GSK announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive scientific opinion for its malaria candidate vaccine Mosquirix.

Is the RTS vaccine used in Sub-Saharan Africa?

While other vaccines tackle viruses or bacteria, RTS,S has been designed to prevent malaria caused by the Plasmodium falciparum parasite, which is most prevalent in sub-Saharan Africa (SSA).